Prostacyclins Within Treatment of Pediatric Pulmonary Hypertension

November 19, 2020

This activity will provide pharmacists, residents, and pharmacy technicians with information in order to help determine how to provide safe and efficacious therapy options for the pediatric patients with pulmonary hypertension. The most recent guidelines for pediatric pulmonary hypertension are recommendations from the American Heart Association and American Thoracic Society, but there have not been any updates since 2015. Traditionally, nitric oxide has been the gold standard of therapy. However, this is a costly inhalation therapy and provides potential complications to patients that require treatment therapy in the outpatient setting. With newer primary literature emerging, prostacyclins have been shown to be more cost effective compared to nitric oxide and have some newer studies demonstrating that it can be used as an alternative therapy or when refractory to nitric oxide therapy. This presentation will review primary literature behind the use of prostacyclin therapy for pediatric pulmonary hypertension and help identify its place in practice.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Review the current guidelines for pediatric pulmonary hypertension
  2. Discuss updates to literature since the published 2015 American Heart Association/American Thoracic Society guidelines for pediatric pulmonary hypertension
  3. Determine where prostacyclins are applicable and indicated as treatment options

Pharmacy technician learning objectives

  1. Identify the pharmacological treatment options for pediatric pulmonary hypertension
  2. Recognize the brand and generic names of the pharmacological options for the treatment of pediatric pulmonary hypertension

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance
Course opens: 
Course expires: 
Event starts: 
11/19/2020 - 12:00pm CST
Event ends: 
11/19/2020 - 1:00pm CST
Ochsner Medical Center
New Orleans, LA
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose
The presenter will discuss off-label use of drugs
Planning committee members
Mersina Grass, PharmD, MS
Clinical Pediatric Pharmacist
Ochsner Medical Center
Bailey Wise, PharmD, BCPS
Clinical Pharmacist
Ochsner Medical Center
Course reviewer
Gretchen Brummel, PharmD, BCPS
Consulting Director, Pharmacy
Malgorzata Labedz, PharmD
PGY1 Pharmacy Practice Resident
Ochsner Medical Center


Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statements:
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-20-218-L01-P
Universal Activity Number: JA0006103-9999-20-218-L01-T
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance


Please login or register to take this course.